Online:
Visits:
Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

CRISPR Market Share Analysis 2016, By End User Application, Forecast to 2022

Tuesday, January 10, 2017 8:19
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Clustered regularly-interspaced short palindromic repeats also known as CRISPR is a gene editing tool. CRIPSR commercialization began in 2012 with emergence of number of startups and venture capitalists and showing their interest in infusing money into this technology. Academic and research firms are the main consumers of CRISPR gene editing tool followed by biotechnology companies. The number of patents for CRISPR is outclassing the patents of other gene editing tools such as ZFN and TALEN. The market is driven by high demand for plasmids, synthetic genes and high quality gene slicing techniques. Growing drug discovery, biotechnology and proteomics markets are also driving the market growth. 

 

For more information about this report: http://www.reportsweb.com/global-crispr-market-insights-opportunity-analysis-market-shares-and-forecast-2016-2022              

 

The market is This is driven by the fact that CRISPR is a new technology which is simple, more efficient and cost effective as compared to its peers. High adoption both in biotech and pharma industry along with high level of research is also responsible for high growth rate.
The market for CRISPR technology is niche. The number of companies are still very less and most of the companies are start-ups which are going through rounds of funding. Some of the major companies include Editas, Intellia, Sigma Eldrich, Oregene, Gene Script, Thermo Fisher Scientific and others. Most of the companies are working on developing CRISPR products along with the approval and commercialization of such products. These companies have successfully attracted major investments from big VC firms and companies such as Google and DuPont. These companies are relying on the disruptive nature of the technology. CRISPR has the capability to open new markets for gene surgery and genetically modified organisms. However, there are major concerns from the scientific community regarding the misuse of such technology in human cloning. Geographically North America leads the market race followed by Europe and Asia Pacific. 

 

Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001329442/sample

 

Companies profiled include
1. Thermo Fisher Scientific
2. Editas Medicine
3. Caribou Biosciences
4. CRISPR therapeutics
5. Intellia
6. Cellectis
7. Horizon discovery PLC
8. Sigma Aldrich
9. Precision biosciences
10. GenScript
11. Sangamo Biosciences Inc.
12. Lonza group limited
13. Integrated DNA technologies
14. New England Biolabs
15. Oregene Technologies
16. Transposgen Biopharmaceuticals

This Publisher report covers
1. Historical data
2. Revenue forecasts, growth rates and CAGR up to 2021
3. Industry Analysis
4. Competitive Analysis
5. Key geographic growth data

 

Company Profiling
1. Thermo Fisher Scientific
2. Editas Medicine
3. Caribou Biosciences
4. CRISPR therapeutics
5. Intellia
6. Cellectis
7. Horizon discovery PLC
8. Sigma Aldrich
9. Precision biosciences
10. GenScript
11. Sangamo Biosciences Inc.
12. Lonza group limited
13. Integrated DNA technologies
14. New England Biolabs
15. Oregene Technologies
16. Transposgen Biopharmaceuticals

 

Inquire before Buying at http://www.reportsweb.com/inquiry&RW0001329442/buying

 

Contact Us:

Call: +1-646-491-9876
Email: [email protected]

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

 

Top Global

 

Top Alternative

 

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.